Novartis Stock

Novartis FCF Margin

The Free Cash Flow Margin of Novartis (NOVN.SW) as of Aug 8, 2026 is 32.27 %. In the previous year, Free Cash Flow Margin was 26.69 % — a change of 20.89% (higher).

FCF Margin

32.27 %

YoY

20.89%

Last updated:

Free Cash Flow Margin of Novartis is 2026 32.27 % . Free Cash Flow Margin of Novartis was 2025 26.69 % . It decreases by 20.89% higher compared to the previous year.
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

Free Cash Flow Margin of Novartis is 32.27 % in 2026.

Free Cash Flow Margin of Novartis changed from 26.69 % to 32.27 %, representing a 20.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Novartis since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Novartis with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Novartis

All Key Metrics — Novartis